Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
SAN DIEGO , May 21, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , May 10, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit D. Munshi , President and Chief Executive Officer, will present at the following investor conferences: Bank of America Merrill Lynch Healthcare Conference in Las Vegas, NV on Thursday, May
View HTML
Toggle Summary Arena Pharmaceuticals and Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound
- Arena's non-core, proprietary, preclinical compound provides strategic fit with Outpost Medicine's expertise in developing products for genitourinary disorders SAN DIEGO and INDIANAPOLIS , May 1, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused
View HTML
Toggle Summary Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting
SAN DIEGO , April 12, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist
View HTML
Toggle Summary Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , March 26, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the completion of its previously announced underwritten public offering of 9,775,000 shares of its common stock at a price to the public of $41.50 per share, including 1,275,000 shares sold
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27
SAN DIEGO , March 23, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 17th Annual Needham Healthcare Conference on Tuesday, March 27 at 3:00 p.m.
View HTML
Toggle Summary Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
SAN DIEGO , March 21, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $41.50 per share. All of the shares are being sold by Arena.
View HTML
Toggle Summary Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO , March 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering. Arena expects to grant the underwriters an option
View HTML
Toggle Summary Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis
- OASIS trial met primary and all secondary endpoints with statistical significance for patients receiving 2 mg dose of etrasimod for 12 weeks - The 2 mg etrasimod group achieved statistically significant improvement in clinical remission - Safety results support potential best-in-class profile -
View HTML
Toggle Summary Arena Pharmaceuticals to Present Phase 1 and Preclinical Data on APD371 in Development for Treatment of Pain Associated with Crohn's Disease at American Pain Society Annual Scientific Summit
- Data from Phase 1 study of APD371 in healthy volunteers demonstrate safety and tolerability - Healthy volunteers did not exhibit psychotropic effects commonly seen with cannabinoids - Preclinical studies show thousand-fold selectivity for CB2 over CB1 receptors SAN DIEGO , March 1, 2018
View HTML